- Home
- NEOV vs GLSI Comparison
NEOV vs GLSI Comparison
Compare NEOV & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEOV
- GLSI
- Stock Information
- Founded
- NEOV 2018
- GLSI 2006
- Country
- NEOV United States
- GLSI United States
- Employees
- NEOV N/A
- GLSI N/A
- Industry
- NEOV Industrial Machinery/Components
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- NEOV Miscellaneous
- GLSI Health Care
- Exchange
- NEOV Nasdaq
- GLSI Nasdaq
- Market Cap
- NEOV 153.9M
- GLSI 149.5M
- IPO Year
- NEOV N/A
- GLSI 2020
- Fundamental
- Price
- NEOV $5.72
- GLSI $11.18
- Analyst Decision
- NEOV Hold
- GLSI Strong Buy
- Analyst Count
- NEOV 1
- GLSI 1
- Target Price
- NEOV N/A
- GLSI $39.00
- AVG Volume (30 Days)
- NEOV 376.6K
- GLSI 92.0K
- Earning Date
- NEOV 11-07-2025
- GLSI 11-13-2025
- Dividend Yield
- NEOV N/A
- GLSI N/A
- EPS Growth
- NEOV N/A
- GLSI N/A
- EPS
- NEOV N/A
- GLSI N/A
- Revenue
- NEOV $8,426,835.00
- GLSI N/A
- Revenue This Year
- NEOV $121.51
- GLSI N/A
- Revenue Next Year
- NEOV $32.79
- GLSI N/A
- P/E Ratio
- NEOV N/A
- GLSI N/A
- Revenue Growth
- NEOV 218.59
- GLSI N/A
- 52 Week Low
- NEOV $1.80
- GLSI $8.06
- 52 Week High
- NEOV $6.11
- GLSI $15.47
- Technical
- Relative Strength Index (RSI)
- NEOV 64.24
- GLSI 52.99
- Support Level
- NEOV $4.65
- GLSI $9.73
- Resistance Level
- NEOV $5.05
- GLSI $10.57
- Average True Range (ATR)
- NEOV 0.45
- GLSI 0.56
- MACD
- NEOV 0.01
- GLSI 0.06
- Stochastic Oscillator
- NEOV 89.56
- GLSI 65.56
About NEOV NeoVolta Inc.
NeoVolta Inc is engaged in designing, manufacturing and sale of high end Energy Storage System which can store and use solar energy via batteries and an inverter at a residential site. Its market place includes solar industry, installers, new construction homebuilders, home remodelers and homeowners.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.